Showing: 1 - 6 of 6 RESULTS

Porter dentist offers free oral cancer screenings for firefighters

As a thank you to local first responders, Porter Family Dentistry is offering free oral cancer screenings to firefighters in Montgomery County for the next several weeks.

The screenings will be held on Fridays when the office is usually closed so that firefighters don’t have to wait.

In 2016, the National Institute for Occupational Safety and Health published a multi-year study of cancer rates in firefighters, and the findings showed that firefighters had a higher number of cancer diagnoses and cancer-related deaths than the general U.S. population. Among the cancers found in the sample of nearly 30,000 firefighters, those most often found were digestive, oral, respiratory, and urinary cancers.

In recent months, firefighters across the country have been traveling to areas, like California, that their help is needed. Dr. Mustafa Yamani of Porter Family Dentistry went to school in California and has fond memories of the nature and beauty of the state.

“It’s such a beautiful place, it’s really sad reading all of the stuff in the news that’s going on there,” Yamani said. “From all around the country they (the firefighters) come together and they provide this service. It’s just amazing what they’re doing and I really appreciate that. I just want to do something for them.”


The generous act of the firefighters inspired him to give back, and since oral cancer screenings are a service his office already offers he decided to give them to firefighters for free.

While this is the first year that the dental office has offered free screenings, Yamani and his wife Sabrina, who is the office manager, plan on making it an annual thing. The trials of 2020 also helped them decide to give back.

“Things seem to be going from bad to worse, to even worse, and it just doesn’t seem to be stopping for our first responders,” Sabrina said. “They’re just being hit with things one after the other.”

Sabrina started by reaching out to fire departments in the east past of Montgomery County to let them know about the opportunity and the response was immediate and positive. Already, the dental office has screenings set up with local firefighters.

Because firefighters are at a higher risk of developing cancer, many departments take an aggressive approach to screenings and check-ups. Early detection is vital. Such is the approach of the East Montgomery County Fire Department where firefighters undergo a National Fire Protection Agency physicals annually.

“It’s huge to us,” Eran Denzler, captain and PIO with the department, said of being able to get the oral screenings for free. “It’s a great show of appreciation for what we do and the risks that we take. Every day we go and put our lives on the line for the community, and for them to give back and worry about our safety is something we’re not used to but it’s much appreciated.”

The department averages around one to two structure fires a week,

Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

– Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups –

– Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% observed for 20 mg and 60 mg doses of GB001, respectively; 23% improvement observed in 40 mg group –

– TITAN Study in chronic rhinosinusitis did not meet primary or secondary endpoints –

– Gossamer to hold webcast to discuss trial results at 8:00 am EDT –

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its Phase 2 TITAN trial in patients with chronic rhinosinusitis.

“While we did not achieve statistical significance on the primary endpoint in the LEDA Study, we are encouraged by the consistent results observed for all three doses of once-daily, oral GB001 therapy across the primary and secondary endpoints,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We believe these data provide important information for designing a well-powered Phase 3 program for GB001 in severe asthma. We plan to engage in global regulatory discussions in order to inform our thinking around potential partnerships or strategic alternatives for this program.”

“The results of the robust LEDA Study are meaningful and help us to further understand the DP2 pathway in asthma,” said Bruce Levy, M.D., Chief, Division of Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. “I believe GB001 as an oral treatment has the potential to serve the high unmet need of patients with uncontrolled severe asthma.”

LEDA Phase 2b Trial Design

The LEDA trial enrolled 480 patients with uncontrolled, moderate-to-severe eosinophilic asthma and assessed the effect of oral GB001 add-on therapy to standard of care over 24 weeks, comparing three dose groups of once-daily, oral GB001 (20 mg, n=120; 40 mg, n=118; and 60 mg, n=122) to placebo (n=120).

The primary endpoint, asthma worsening, included five components and was chosen for its sensitivity in detecting deterioration in clinical outcome measures known to be correlated with exacerbations. A patient was considered to have experienced asthma worsening if they met any of the five components by Week 24. This endpoint has previously been used in the context of steroid withdrawal studies, including a prior Phase 2 trial of GB001.

LEDA Primary and Secondary Endpoint Results

The primary endpoint of the trial was not met, though consistent and meaningful numeric reductions in the odds of asthma worsening as compared to placebo were observed across all GB001 groups: 33% (p=0.1425), 32% (p=0.1482), and 35% (p=0.1086), for the GB001 20 mg, 40 mg, and 60 mg groups, respectively. In addition, statistically significant improvements in the key secondary endpoint of time to first asthma worsening as compared to placebo

Prodrugs Infusion Beats Oral PD Therapy for Motor Symptoms

A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson’s disease (PD) motor symptoms during all waking hours for patients with advanced disease, according to a new study.

The beneficial effects of these phosphate prodrugs of levodopa and carbidopa were most noticeable in the early morning, results of the phase 1B study showed.

As PD progresses and dosing of oral levodopa/carbidopa (LD/CD) increases, its therapeutic window narrows, resulting in troublesome dyskinesia at peak drug levels and tremors and rigidity when levels fall.

“Foslevodopa/foscarbidopa shows lower OFF time than oral levodopa/carbidopa, and this was statistically significant. Also, foslevodopa/foscarbidopa (fosL/fosC) showed more ON time without dyskinesia compared to oral levodopa/carbidopa. This was also statistically significant,” lead author Sven Stodtmann, PhD, of AbbVie GmbH & Company KG, Ludwigshafen, Germany, reported in his recorded presentation at the Movement Disorders Society’s 23rd International Congress of Parkinson’s Disease and Movement Disorder (Virtual) 2020.

The analysis included 20 patients, and all data from these individuals were collected between 4:30 AM and 9:30 PM.

Participants were 12 men and 8 women, aged 30 to 80 years, with advanced, idiopathic PD responsive to levodopa but inadequately controlled on their current stable therapy, having a minimum of 2.5 OFF hours/day. Mean age was 61.3 ± 10.5 years (range 35-77 years).

In this single arm, open-label study, they received subcutaneous infusions of personalized therapeutic doses of fosL/fosC 24 hours/day for 28 days after a 10- to 30-day screening period during which they recorded LD/CD doses in a diary and had motor symptoms monitored using a wearable device.

Following the screening period, fosL/fosC doses were titrated over up to 5 days, with subsequent weekly study visits, for a total time on fosL/fosC of 28 days. Drug titration was aimed at maximizing functional ON time and minimizing the number of OFF episodes while minimizing troublesome dyskinesia.

Continuous infusion of fosL/fosC performed better than oral LD/CD on all counts.

“The OFF time is much lower in the morning for people on foslevodopa/foscarbidopa [compared with oral LD/CD] because this is a 24-hour infusion product,” Stodtmann explained.

The effect was maintained over the course of the day with little fluctuation with fosL/fosC, OFF periods never exceeding about 25% between 4:30 AM and 9 PM. For LD/CD, OFF periods were highest in the early morning and peaked at about 50% on a 3- to 4-hour cycle during the course of the day.

Increased ON time without dyskinesia varied between about 60% and 80% during the day with fosL/fosC, showing the greatest difference between fosL/fosC and oral LD/CD in the early morning hours.

“ON time with nontroublesome dyskinesia was lower for foscarbidopa/foslevodopa compared to oral levodopa/carbidopa, but this was not statistically significant,” Stodtmann said. ON time with troublesome dyskinesia followed the same pattern, again, not statistically significant.

Looking at the data another way, the investigators calculated the odds ratios of motor symptoms using fosL/fosC compared with oral LD/CD. Use of fosL/fosC was associated with a 59% lower risk of being in the OFF state during the day compared with

Diamond Dental Associates LLC, Has The Best Flemington Dentist For Oral Healthcare And Treatment Needs

Diamond Dental Associates LLC, Has The Best Flemington Dentist For Oral Healthcare And Treatment Needs

Flemington, NJ – Members of the Flemington, NJ community who wish to sport the best smiles and enjoy the advantages of top oral health can rest assured that Diamond Dental Associates LLC has the best dentists in the area to deliver these premium services at the most affordable prices. At Diamond Dental Associates LLC, the dental team focuses on providing premium quality dental care and treatment solutions to patients while delivering the best dental experience in the process.

As the leading dental clinic in the area, Diamond Dental Associates LLC has a team of dentists with over three decades of experience who are on the ground to listen to oral health complaints from patients and address the problem. At Diamond Dental Associates LLC, the team employs the use of the latest dental technologies to establish diagnosis and craft treatment plans that are most suitable for the needs of each patient.

Promising the very best dental experience, the top Flemington Dentist at the clinic said: “Here at Diamond Dental Associates LLC, we pledge to provide the finest personal service using state of the art technology for our patients, who will always be welcomed to a warm and caring environment. At Diamond Dental Associates we change lives one smile at a time. We are committed to making every interaction with our patients a positive one. We respect and acknowledge your concerns about the dental treatment you will receive. We recognize that it is difficult for highly fearful people to visit a dental office for needed treatment and we offer services that help you to feel confident that the treatment we provide is in your best interests and fits in with your preferences, lifestyle, and monetary investment.”

As a dental clinic that is constantly working on new ways to address the dental care and treatment needs of patients, Diamond Dental Associates LLC – Flemington Dentist has expanded the services offered to include general dentistry practice which focuses on improving oral health and protecting the mouth from common debilitating conditions. As part of the general dentistry services offered, patients will get to enjoy routine dental examinations, oral cancer screening, teeth cleaning, dental sealants, and more.

Added to this, the dental team at Diamond Dental Associates LLC also offers a wide range of cosmetic dental solutions aimed at improving the appearance and appeal of the teeth. As part of the cosmetic dental solutions offered, patients are welcomed into the clinic to enjoy teeth whitening services aimed at brightening the teeth and smile; cosmetic bonding used to restore decayed teeth, strengthen a weak tooth, close spaces between the teeth, and alter the shape and/or size of the tooth.

The dentists also offer dental veneers that are used to cover up blemishes, chips, cracks, and tooth discoloration; dental implants for restoration of missing or lost teeth; as well as sports mouthguards and sleep apnea treatment.

Visit Diamond Dental Associates LLC at North, 334 NJ-31 #1, Flemington, NJ 08822, or call 908-838-0004. For more information, send an email

Dental, oral health vital amid pandemic: Dentist

ANKARA

A Turkish dentist on Wednesday warned that if oral hygiene and health are not taken seriously, the novel coronavirus pandemic may deteriorate as infections accelerate and symptoms become more severe.

The mouth and nose are the first places that the coronavirus enters the body, Murat Akkocaoglu told Anadolu Agency, underlining the importance of oral and dental health during the pandemic.

Many have asked whether dental treatment is still safe amid the outbreak, he noted, adding that as long as dental clinics take all the necessary hygiene measures, there is no need for worry.

“Hygiene rules should be increased even more, especially during pandemics,” Akkocaoglu said, stressing that areas used during treatment must be disinfected after each use and have the equipment needed to easily provide disposable materials.

Larger clinics where distance can be maintained between patients would be more suitable to curb infection.

“Clinics should also have a personal appointment system so that the doctor can be reached with minimum contact before treatment.”

Better oral health, better body immunity

Maintaining good oral and dental health is important to prevent not only COVID-19, but other infectious afflictions as well, Akkocaoglu said.

”The mouth is the entryway to the body. Much more attention should be paid to oral and dental health and hygiene during the pandemic. The first places COVID-19 enters the human body are the mouth and nose. In short, protecting the entrance from infections is especially vital.”

However, he warned that using excessive amounts of substances like vinegar and alcohol risked damaging healthy tissue barriers.

“I recommend regular brushing of the teeth rather than other practices,” he said.

*Writing by Yunus Girgin in Ankara



Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.

(function() { var e = document.createElement('script'); e.src = "https://connect.facebook.net/tr_TR/all.js"; e.async = true; document.getElementById('fb-root').appendChild(e); }());

Source Article

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

  • The Phase 2a trial for the treatment of NASH met its primary efficacy endpoint; PXL770-treated patients achieved statistically significant improvement in the relative decrease in liver fat mass measured by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) at 12-weeks with a greater response in patients with type 2 diabetes1

  • Key secondary measures in PXL770-treated patients included statistically significant observed improvements in liver enzymes – alanine transaminase (ALT) and hemoglobin A1c (HbA1c)

  • PXL770 was observed to be safe and well tolerated; profile supports further evaluation for combination use

  • First human clinical assessment of a direct AMPK activator; results support potential for development in NASH including key high-risk subgroups (patients with type 2 diabetes) and utility of AMPK activation in other chronic and rare metabolic diseases

  • Conference call in English scheduled today for 12:00 pm EDT (New York time) / 6 pm CEST (Paris time)

POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced positive top-line results for STAMP-NAFLD, the PXL770 Phase 2a trial. The Phase 2a trial was a 12-week, randomized, parallel group study, in 120 presumed NASH patients with or without diabetes. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator. AMPK is a master regulator of several important metabolic pathways, including lipid metabolism, glucose control and inflammation, and is a novel target for NASH and a range of other chronic and rare metabolic diseases.

“The underlying pathophysiological drivers of nonalcoholic fatty liver disease (NAFLD) and NASH are highly complex and support the need for development of novel therapies acting on different targets that can address a variety of key disease drivers,” said Vlad Ratziu, MD, PhD, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital. “AMPK activation is a differentiated approach for NASH and these results demonstrate that it could have a beneficial role in controlling key pathways that lead to liver injury. By also directly targeting inflammation and fibrogenesis, as demonstrated in preclinical models including human cells, PXL770 has the potential to independently impact multiple disease components. As an oral agent, PXL770 also has the potential to be used in combination with other agents, which could provide for broad treatment of this disease.”

Summary of STAMP-NAFLD PXL770 Phase 2a Study Results

STAMP-NAFLD was a 12-week randomized, placebo-controlled, parallel group trial in 120 presumed NASH patients, with or without diabetes, which evaluated three dosing regimens of PXL770 versus placebo. Primary enrollment criteria were evidence of hepatic steatosis (NAFLD) based on a controlled attenuation parameter (CAP) score of >300 db/m measured by MRI-PDFF. Patients were randomized into four groups: PXL770 at 250 mg once-daily (QD); 250 mg twice-daily (BID); 500 mg once-daily (QD) versus patients who received placebo.

The Phase 2a trial met its primary efficacy endpoint; PXL770 was observed to produce a statistically significant mean relative decrease of 18% in liver fat mass from baseline at 12-weeks in the 500 mg QD dose